- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 5,386
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Interventions
- CB-839, Cabozantinib, Placebo
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- IDEC-114
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Rochester, Minnesota • Buffalo, New York + 1 more
- Conditions
- Lymphoma, Nonneoplastic Condition
- Interventions
- bleomycin sulfate, filgrastim, ABVD regimen, BEACOPP regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 423
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more
- Conditions
- Obesity, Overweight
- Interventions
- Choices
- Behavioral
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 8 Years to 11 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Pain; Dialysis Catheter
- Interventions
- CentrosFLO Long Term Hemodialysis Catheter
- Device
- Lead sponsor
- Merit Medical Systems, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Colton, California • Los Angeles, California + 4 more
- Conditions
- Alzheimer's Disease
- Interventions
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 49
- States / cities
- Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Fibrocystic Disease of Breast, Fibrocystic Changes of Breast, Fibrocystic Mastopathy, Pain
- Interventions
- IoGen (molecular iodine)
- Drug
- Lead sponsor
- Symbollon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Osteoarthritis
- Interventions
- PLA-695
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Needle core biopsy
- Procedure
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 60
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more
- Conditions
- Bladder Cancer, Transitional Cell Carcinoma, Metastasis
- Interventions
- Vinflunine, Gemcitabine, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 53 more
- Conditions
- Insomnia, Attention Deficit Hyperactivity Disorder
- Interventions
- eszopiclone
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 89
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Carson, California + 70 more
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Interventions
- Relamorelin, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 70
- States / cities
- Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- K-808 (Dose A), K-808 (Dose B), Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- Interventions
- HTD1801, Placebo
- Drug
- Lead sponsor
- HighTide Therapeutics (Hong Kong) Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
- Interventions
- CardioMEMS™ HF System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 125
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- MK-3655, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 48
- States / cities
- Tucson, Arizona • North Little Rock, Arkansas • Canoga Park, California + 37 more
- Conditions
- Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Fibrosis Foundation
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,004 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Cow Milk Allergy
- Interventions
- Neocate Infant, new Neocate
- Dietary Supplement
- Lead sponsor
- Nutricia North America
- Industry
- Eligibility
- 1 Day to 8 Months
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 22
- States / cities
- Chandler, Arizona • Tucson, Arizona • Bentonville, Arkansas + 18 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-561, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Ravagalimab 600 mg, Ravagalimab 300 mg
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Huntington Beach, California • Lakewood, California + 9 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 18 Months to 29 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 3,154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 208
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more